From: Effect of antivenom therapy of Rhabdophis tigrinus (Yamakagashi snake) bites
Population characteristics | Values |
---|---|
Age (years) | 37.5 (43.8) |
Gender, male, n (%) | 33 (97.1) |
Date of getting injury (year) | |
1973–1999 | 25 (73.5) |
2000–2013 | 9 (26.5) |
Clinical symptoms | |
Nasal bleeding, n (%) | 4 (11.8) |
Gum bleeding, n (%) | 15 (44.1) |
Bleeding from the bite sites, n (%) | 27 (79.4) |
Headache, n (%) | 6 (17.6) |
Laboratory data | |
Platelet counts (×104/mm3) | 10.7 (10.4) |
Fibrinogen (mg/dL) | 35 (30) |
PT-INR | 5 (4.38) |
FDP (μg/mL) | 200 (180) |
DIC score | 5(3) |
Treatment | |
Heparin, n (%) | 14 (41.2) |
FFP, n (%) | 8 (25.0) |
PE, n (%) | 4 (11.8) |
Antivenom, n (%) | 19 (55.9) |
Time interval between getting Yamakagashi bites and antivenom administration (h) | 32 (31) |
Severe adverse effects related to antivenom | 0 (0) |
Outcome | |
Mortality, n (%) | 4 (11.8) |
Hospital stay | 9.5 (9.5) |
Renal failure requiring hemodialysis, n (%) | 7 (20.6) |